2018
Increased non‐AIDS mortality among persons with AIDS‐defining events after antiretroviral therapy initiation
Pettit AC, Giganti MJ, Ingle SM, May MT, Shepherd BE, Gill MJ, Fätkenheuer G, Abgrall S, Saag MS, Del Amo J, Justice AC, Miro JM, Cavasinni M, Dabis F, Monforte AD, Reiss P, Guest J, Moore D, Shepherd L, Obel N, Crane HM, Smith C, Teira R, Zangerle R, Sterne JA, Sterling TR, investigators F. Increased non‐AIDS mortality among persons with AIDS‐defining events after antiretroviral therapy initiation. Journal Of The International AIDS Society 2018, 21: e25031. PMID: 29334197, PMCID: PMC5810321, DOI: 10.1002/jia2.25031.Peer-Reviewed Original ResearchConceptsAdjusted hazard ratioAntiretroviral therapy initiationAIDS mortalityAdjusted hazardCohort CollaborationTherapy initiationAntiretroviral Therapy Cohort CollaborationHIV-1 infectionTreatment-naïve adultsCause of deathMarginal structural modelsART initiationHIV protocolMetabolic deathHazard ratioChronic inflammationRisk factorsCoding CausesSubsequent deathMortalityAIDSCommon pathwayDeathUnmeasured confoundersCause
2012
Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries
del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA. Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries. Clinical Infectious Diseases 2012, 54: 1364-1372. PMID: 22460971, PMCID: PMC3404691, DOI: 10.1093/cid/cis203.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountCohort StudiesDeveloped CountriesDrug Therapy, CombinationEuropeFemaleHIV InfectionsHIV SeropositivityHumansImmune Reconstitution Inflammatory SyndromeIncidenceMaleMiddle AgedMycobacterium tuberculosisPneumocystis cariniiPneumonia, PneumocystisRNA, ViralTuberculosisUnited StatesViral LoadConceptsImmune reconstitution inflammatory syndromeCD4 cell countCells/μL.HIV RNA levelsHazard ratioTuberculosis incidenceCART initiationCell countAntiretroviral therapyTime-varying CD4 cell countBaseline CD4 cell countAIDS-free individualsEffects of CARTLow tuberculosis incidenceMonths of ARTReconstitution inflammatory syndromeHIV-positive patientsRNA levelsHIV-positive individualsHuman immunodeficiency virusHIV-CAUSAL CollaborationInflammatory syndromeImmunodeficiency virusInverse probability weightingPositive individuals
2011
Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening
Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, Brooks JT, Deeks SG, French A, Gange S, Gebo KA, Gill M, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Klein MB, Martin JN, Rodriguez B, Silverberg MJ, Willig JH, Eron JJ, Goedert JJ, Hogg RS, Justice AC, McKaig RG, Napravnik S, Thorne J, Moore RD. Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. The Journal Of Infectious Diseases 2011, 204: 893-901. PMID: 21849286, PMCID: PMC3156918, DOI: 10.1093/infdis/jir421.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapy (HAART) initiationAntiretroviral therapy initiationInjection drug useHIV-1 RNAHuman immunodeficiency virusHAART initiationTuberculosis riskBaseline CD4Therapy initiationMale sexNonwhite raceHispanic ethnicityDrug useBaseline HIV-1 RNAMonths of HAARTLow-incidence settingsProportional hazards modelActive tuberculosisLymphocyte countParametric survival modelsTuberculosis screeningImmunodeficiency virusBlack raceLymphocytes/Risk factors
2005
Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America
Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, Dabis F, Reiss P, Kirk O, Bernasconi E, Grabar S, Justice A, Staszewski S, Fätkenheuer G, Sterne JA. Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America. Clinical Infectious Diseases 2005, 41: 1772-1782. PMID: 16288403, DOI: 10.1086/498315.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiretroviral Therapy, Highly ActiveEuropeFemaleHIV InfectionsHumansIncidenceMaleNorth AmericaTuberculosisConceptsIncidence of tuberculosisMonths of HAARTMultivariable analysisMultivariable Poisson regression modelsInitiation of HAARTLevel of immunodeficiencyLower baseline CD4Active antiretroviral therapyHIV RNA levelsRisk of tuberculosisInjection drug usersMode of transmissionPoisson regression modelsBaseline CD4HAART initiationHigher CD4Antiretroviral therapyTB epidemicIncidence rateCopies/HAARTDrug usersPatientsTuberculosisCD4